SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-019014
Filing Date
2023-11-14
Accepted
2023-11-14 16:05:39
Documents
88
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ganx-20230930x10q.htm   iXBRL 10-Q 1892557
2 EX-10.3 ganx-20230930xex10d3.htm EX-10.3 119258
3 EX-31.1 ganx-20230930xex31d1.htm EX-31.1 11318
4 EX-31.2 ganx-20230930xex31d2.htm EX-31.2 10531
5 EX-32.1 ganx-20230930xex32d1.htm EX-32.1 10057
  Complete submission text file 0001558370-23-019014.txt   7585812

Data Files

Seq Description Document Type Size
6 EX-101.SCH ganx-20230930.xsd EX-101.SCH 50960
7 EX-101.CAL ganx-20230930_cal.xml EX-101.CAL 60067
8 EX-101.DEF ganx-20230930_def.xml EX-101.DEF 162287
9 EX-101.LAB ganx-20230930_lab.xml EX-101.LAB 464273
10 EX-101.PRE ganx-20230930_pre.xml EX-101.PRE 346234
82 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20230930x10q_htm.xml XML 1188741
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

IRS No.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40237 | Film No.: 231405911
SIC: 2834 Pharmaceutical Preparations